Clinical Trial

CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 18, 2025 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This prospective, single-arm study aims to investigate the efficacy and safety of CapeOX combined with Bevacizumab plus Anti-PD1 Antibody as neoadjuvant therapy for locally recurrent colorectal cancer
Trial Details
NCT Number NCT06881537
Lead Sponsor Shanghai Changzheng Hospital
Conditions Locally Recurrent Colorectal Cancer
Enrollment 15 participants
Start Date 2024-06-01
Primary Completion 2025-06-30 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-03-18